MBX Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that MBX Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($21.62M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($19.41M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($19.41M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($23.88M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($23.88M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($23.88M) | Aug 7, 2025 |
| Q2 | 2025 | Dec 31, 2024 | ($61.90M) | Aug 7, 2025 |
| Q1 | 2025 | Dec 31, 2024 | ($32.60M) | May 12, 2025 |
| Q3 | 2025 | Dec 31, 2024 | ($61.90M) | Nov 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($18.14M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($15.86M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($15.86M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($12.34M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($12.34M) | Aug 7, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($12.34M) | Nov 6, 2025 |
| Q3 | 2024 | Dec 31, 2023 | ($32.60M) | Nov 7, 2024 |
| Q3 | 2024 | Sep 30, 2023 | ($10.16M) | Nov 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($7.61M) | Nov 7, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($5.95M) | Nov 7, 2024 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($23.93M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($21.81M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($26.53M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($19.61M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($16.66M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($13.31M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($10.95M) | Nov 7, 2024 |